Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 321-328

  Guiu, S ^a   Liegard, M ^a   Favier, L ^a   van Praagh, I ^b   Largillier, R ^c   Weber, B ^d   Coeffic, D ^e   Moreau, L ^f   Priou, F ^g   Campone, M ^h   Gligorov, J ⁱ   Vanlemmens, L ^j   Trillet Lenoir, V ^k   Arnould, L ^a   Coudert, B ^a  

^a IFR No 100   (France)

^b Jean Perrin Centre   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d Department of Medical Oncology   (France)

^e Institut Daniel Hollard   (France)

^f Clinique des Domes   (France)

^g CH Les Oudairies ^*  (France)

^h Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

ⁱ HÔPITAL TENON   (France)

^j Institut O Lambret   (France)

^k UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

more..

Author keywords

Breast cancer; Follow up; HER2; Neoadjuvant; Primary systemic therapy; Trastuzumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 79251559731     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq397     Document Type: Article

References (37)

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
2. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 2004; 11: 139-147.
3. Coudert B, Arnould L, Moreau L et al. Preoperative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006; 17: 409-414.
4. Coudert BP, Largillier R, Arnould L et al. Neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of a GETN(A) Group and OSMO Multicenter Phase II Trial (GETN[A]-1 trial) 547. J Clin Oncol 2007; 25: 2678-2684.
5. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974-976.
6. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
7. Menard S, Balsari A, Casalini P et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002; 8: 520-525.
8. Tagliabue E, Agresti R, Carcangiu ML et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003; 362: 527-533.
9. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005; 23: 4265-4274.
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
13. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
14. Leyland-Jones B, Gelmon K, Ayoub JP et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-3971.
15. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
16. Kaufmann M, von MG, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-1934.
17. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
18. Buzdar AU, Valero V, Ibrahim NK et al. neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13: 228-233.
19. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
20. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol 2010; 28: 2024-2031.
21. Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-1838.
22. Shimizu C, Masuda N, Yoshimura K et al. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. Jpn J Clin Oncol 2009; 39: 484-490.
23. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
24. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-5692.
25. Slamon DJ, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. In Cancer Research 69 (Suppl). 2009. SABCS 2009, San Antonio, TX.
26. Costa RB, Kurra G, Greenberg L et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010 Mar 29 [Epub ahead of print] doi:10.1093/annonc/mdq096.
27. Spielmann M, Roche H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27: 6129-6134.
28. Wenzel C, Hussian D, Bartsch R et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004; 130: 400-404.
29. Paluch-Shimon S, Wolf I, Goldberg H et al. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer. Acta Oncol 2008; 47: 1564-1569.
30. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
31. Fisher B, Brown A, Mamounas EP et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B18. J Clin Oncol 1997; 15: 2483-2493.
32. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or operative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
33. Arnould L, Arveux P, Couturier J et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007; 13: 6404-6409.
34. Giuliani R, Durbecq V, Di LA et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007; 43: 725-735.
35. Chollet P, Abrial C, Durando X et al. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J 2008; 14: 128-132.
36. Carey LA, Metzger R, Dees EC et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97: 1137-1142.
37. Jeruss JS, Mittendorf EA, Tucker SL et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008; 26: 246-252.